Diffuse eruptive spider angiomas possibly associated with long-term lercanidipine therapy: A case report Authors: Diala Haykal Published: 2026 Introduction Spider angiomas are common superficial vascular lesions characterized by a central arteriole with radiating telangiectasias. They are typically associated with hyperestrogenic states, chronic liver disease, and, less frequently, genetic predisposition. Drug-induced vascular reactions are also recognized in dermatology; however, diffuse eruptive spider angiomas associated with antihypertensive therapy remain poorly documented. Lercanidipine is a dihydropyridine calcium-channel blocker widely used in the management of hypertension. Although vasodilatory adverse effects such as flushing and peripheral edema are well known, diffuse spider angiomas have not, to our knowledge, been previously described in association with this medication. We report a case of sudden-onset widespread spider angiomas occurring in a patient receiving long-term lercanidipine therapy, suggesting a possible drug-related vascular dysregulation. Case report A 62-year-old woman presented with the progressive eruptive appearance of multiple vascular lesions involving the face, trunk, and upper extremities over several weeks. The lesions were asymptomatic and were not associated with pruritus, bleeding, pain, or systemic manifestations. The patient reported no personal history of similar dermatologic findings. Clinical examination revealed numerous spider angiomas distributed across the face, chest, back, and upper extremities. No palmar erythema, jaundice, ascites, hepatomegaly, or other clinical stigmata of chronic liver disease were observed. The lesions demonstrated the characteristic morphology of a central arteriole with radiating superficial capillaries. Blanching upon pressure was observed, supporting the diagnosis of spider angiomas. No additional cutaneous abnormalities were noted. The patient’s medical history was unremarkable for liver disease, alcohol misuse, endocrine disorders, pregnancy, estrogen therapy, connective tissue disease, or hereditary vascular conditions. She had been receiving lercanidipine for hypertension for approximately 10 years at a dose of 10 mg daily. Five years before presentation, the dosage had been increased to 20 mg daily as part of a therapeutic escalation for blood pressure control. No other recent medication changes or newly introduced treatments were reported.1, 2, 3 Laboratory investigations were within normal limits, including complete blood count, liver function tests, renal function, coagulation profile, fasting glucose, hormonal evaluation, and thyroid function tests. No evidence of hepatic dysfunction, endocrine abnormalities, or systemic disease was identified. Additional radiologic investigations showed no significant abnormalities. Although histopathologic confirmation could have provided additional diagnostic support, biopsy was deferred because the lesions were clinically typical, blanchable on examination, and cosmetically sensitive given their facial distribution. Given the absence of classical etiologies and the possibility of a medication-related vascular reaction, lercanidipine was discontinued in coordination with the patient’s cardiologist. The patient subsequently underwent vascular laser treatment using a 1064-nm long-pulsed Nd:YAG laser.4,5 At 1-month follow-up, marked clinical improvement was observed, with significant regression of the vascular lesions and absence of newly developed angiomas. Continued improvement was further confirmed at 70-day follow-up, with persistent regression of the lesions and no evidence of recurrence (Fig 1, Fig 2, Fig 3, Fig 4, Fig 5, Fig 6, Fig 7, Fig 8, Fig 9). Diffuse distribution of multiple spider angiomas involving the face and trunk at presentation. Diffuse distribution of multiple spider angiomas involving the face and trunk at presentation. Diffuse distribution of multiple spider angiomas involving the face and trunk at presentation. Significant regression of spider angiomas 1 month after discontinuation of lercanidipine therapy and Nd:YAG laser treatment. Significant regression of spider angiomas 1 month after discontinuation of lercanidipine therapy and Nd:YAG laser treatment. Significant regression of spider angiomas 1 month after discontinuation of lercanidipine therapy and Nd:YAG laser treatment. Persistent improvement and absence of recurrence at 70-day follow-up. Persistent improvement and absence of recurrence at 70-day follow-up. Persistent improvement and absence of recurrence at 70-day follow-up. Discussion Spider angiomas are traditionally linked to hormonal imbalance, hepatic dysfunction, and angiogenic vascular signaling. Their pathogenesis is believed to involve alterations in superficial vascular regulation and endothelial activity. In the present case, extensive biological investigations excluded the most common underlying causes, including hepatic and endocrine disorders.6 Lercanidipine is a dihydropyridine calcium-channel blocker that exerts potent peripheral vasodilatory effects through inhibition of calcium influx into vascular smooth muscle cells. Vasodilation-related adverse events, including flushing and edema, are well recognized with this drug class. It is plausible that prolonged vascular dilation and endothelial dysregulation may contribute to the development of superficial vascular ectasias such as spider angiomas in predisposed individuals. Calcium-channel blockers may influence superficial cutaneous microcirculation through persistent precapillary vasodilation and altered endothelial reactivity. Chronic vascular dilation may theoretically facilitate the development of superficial vascular ectasias in susceptible individuals, particularly after prolonged exposure or dose escalation.7,8 Although the temporal relationship in this case is atypical given the long duration of exposure, the sudden onset of diffuse lesions in the absence of other identifiable causes raises the possibility of a medication-related vascular phenomenon. However, causality cannot be definitively established from a single observation. An additional limitation is that discontinuation of lercanidipine and Nd laser therapy were performed concurrently. Because vascular laser treatment directly targets superficial vascular lesions, the relative contribution of medication withdrawal versus laser therapy to the observed improvement cannot be determined. Therefore, the clinical regression should not be interpreted as definitive evidence of pharmacological dechallenge. Histopathologic confirmation was not obtained because the lesions were clinically characteristic. Although follow-up remained relatively short, additional evaluation at 70 days demonstrated sustained clinical improvement without recurrence. Although no previous PubMed-indexed case specifically linking lercanidipine to diffuse spider angiomas was identified, calcium-channel blockers have previously been associated with telangiectatic cutaneous reactions. Amlodipine-induced photodistributed telangiectasia has been reported, and a review of calcium-channel blocker-induced telangiectasia described similar vascular eruptions with this pharmacological class.1,9, 10, 11 Felodipine-induced facial telangiectasia has also been described.12 These reports support the plausibility that dihydropyridine calcium-channel blockers may, in rare cases, promote superficial vascular ectasia through persistent vasodilation and altered cutaneous microvascular reactivity. Using standard pharmacovigilance principles, the association in this case would best be classified as a possible drug-related adverse reaction because of the compatible clinical pattern, exclusion of major alternative etiologies, and improvement following drug discontinuation, despite the presence of confounding therapeutic intervention. Conclusion This case describes diffuse eruptive spider angiomas occurring in a patient receiving long-term lercanidipine therapy. Although a causal relationship cannot be confirmed, the absence of classical etiologies raises the possibility of a medication-associated vascular reaction. Clinicians should consider medication history when evaluating eruptive vascular lesions. Further studies are needed to clarify the potential relationship between calcium-channel blockers and spider angiomas. Conflicts of interest None disclosed. Footnotes Funding sources: None. Patient consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying clinical images. The patient was informed of the nature of the publication. IRB approval status: Not applicable. References